ViroCell Manufactured a GMP Lentiviral Vector for UCL to Accelerate Research Into Prevention of Relapse in Childhood Blood Cancer

Contributed by: Business Wire

Logo

Tags

Other Health

Research

Oncology

Other Manufacturing

Genetics

Clinical Trials

Science

Biotechnology

Stem Cells

Manufacturing

Other Science

Health

More Like This

ViroCell and Great Ormond Street Hospital Poised to Unlock Clinical Trial ‘Backlog’ Following MHRA Manufacturing Approval

ViroCell Biologics Completes Oversubscribed Financing

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

ViroCell Biologics Appoints Viral Vector Expert as Special Advisor

PR Newswire associated0

AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and other CD123 Hematological Malignancies

ViroCell Biologics Expands U.S. Business Development Team With Two New Appointments

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

ViroCell Biologics to Host Panel Event at 2024 Cell & Gene Meeting on the Mesa